Children with eczema face a 28% higher likelihood of diagnosed sleep disturbance, according to a study presented at the American College of Allergy, Asthma and Immunology annual meeting in Boston and reported by Contemporary Pediatrics.
The analysis drew on electronic health records for a large pediatric cohort. Eczema appeared in 14.5% of patients and sleep disturbance in 10.3%; both conditions were recorded together in 1.8% of children. Roughly 12% of those with eczema carried a sleep-disturbance diagnosis versus about 10% of those without. The adjusted odds ratio was 1.28 (95% CI, 1.15–1.42; P < .001). Neither a mental-health diagnosis nor the presence of other atopic conditions significantly modified the association.
“Clinicians should ask families about sleep during eczema visits because earlier recognition could inform treatment planning,” the investigators wrote in their ACAAI news release.
The findings line up with earlier survey data showing sleep problems affect an estimated 60% of children with atopic dermatitis, rising during flares. A 2021 cross-sectional study of 180 parent–child dyads put the prevalence at 66.9% among U.S. children aged 5 to 17 with AD — approximately 3.1 million children — and linked itch intensity and lower household income to parent-reported sleep disturbance. Poor sleep in that sample correlated with depression, anxiety, fatigue and inattention.
Sleep is now tracked as a patient-important outcome in AD management. Evidence reviews underpinning the 2023 AAAAI/ACAAI Joint Task Force practice parameters assessed sleep alongside disease severity, itch and quality of life, and the guideline issued 25 recommendations spanning topical therapy, bleach baths, dietary elimination, allergen immunotherapy and systemic treatments.
The authors call for prospective studies using validated sleep measures stratified by AD severity to clarify which children are most at risk.